(Q68272896)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

title

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

main subject

phase II clinical trial

1 reference

non-small-cell lung carcinoma

inferred from title

1 reference

1 reference

S Saxman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

P J Loehrer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

K Logie

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

D Stephens

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

F Workman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

D Scullin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

L H Einhorn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

R Ansari

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

publication date

1 August 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

number of pages

4

1 reference

Investigational New Drugs

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

page(s)

253-256

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00176978

23 September 2019

exact match

0 references

cites work

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

12 December 2020

Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Chronic daily administration of oral etoposide--a phase I trial

1 reference

12 December 2020

Etoposide--an effective single drug for treating bronchogenic carcinoma

1 reference

12 December 2020

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

1 reference

12 December 2020

Phase II study of daily oral etoposide in refractory germ cell tumors

1 reference

12 December 2020

A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study

1 reference

12 December 2020

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

1 reference

12 December 2020

Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma

1 reference

12 December 2020

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

1 reference

12 December 2020

Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00176978

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1664423%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

1 reference